摘要
联合抗反转录病毒治疗(cART)已经使艾滋病成为一种慢性可控性传染病。cART虽然可以使病毒得到抑制,但需终身服药。治疗前耐药率的增加、药物不良反应、每日口服药物的依从性等仍是治疗HIV的主要挑战。基于此,新的抗病毒药物的不断研发,ART方案不断优化,抗病毒药物的有效性、安全性、简便性和耐药屏障也不断提高。复方片剂、新治疗靶点药物和长效药物是目前研发的主要趋势。本文概述了ART的最新进展,以期为临床提供参考。
The success of combination antiretroviral therapy(cART)has transformed AIDS to a chronic and manageable infectious disease.Despite significant viral load suppression obtained by cART,lifelong medication is still required.Major challenges still remained,including the increasing rate of viral resistance before treatment,adverse drug reactions and compliance with daily oral drugs.Thus,new antiviral drugs have been continuously developed.ART regimens have been continuously optimized.The efficacy,safety,simplicity and drug resistance barrier of antiviral drugs have been continuously improved.Combination tablets,new therapeutic target drugs and long-acting drugs are the main trends in research and development.This article reviews the latest progress of ART drugs in order to provide reference for clinical practice.
作者
梁雪蕾
李群
肖晴
劳晓洁
张福杰
LIANG Xuelei;LI Qun;XIAO Qing;LAO Xiaojie;ZHANG Fujie(Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China;Clinical Center for HIV/AIDS,Capital Medical University,Beijing,100015)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2022年第11期1321-1325,共5页
Chinese Journal of Aids & STD
基金
“十三五”国家科技重大专项(2018ZX10302-102)
北京市医管中心项目(DFL20191802)
北京市医院管理局临床医学发展专项(ZYLX202126)
首都卫生发展科研专项(2020-2-2174)。
